Navigation Links
Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
Date:4/22/2010

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC (Abstracts 3698 and 5534).

"This research continues to expand our understanding of the activity and potential clinical benefits of improved cancer therapeutics based on our proprietary technologies; the CombiPlex® platform and the nanoparticle prodrug delivery platform," said Scott Jackson, chief executive officer of Celator Pharmaceuticals.  "The work done with CPX-351 helps explain the encouraging anti-leukemic activity we are seeing in Phase 2 clinical studies and the results seen with HDPN contributed to this product being selected for study by the NCI's Nanotechnology Characterization Laboratory."

In the first presentation, researchers reported on the circulation characteristics and anti-tumor activity of HDPN in mice bearing HT-29 human colorectal tumor xenografts.  Two nanoparticle preparations of the docetaxel pro-drug demonstrated significantly greater plasma half-lives than docetaxel formulated in polysorbate 80, the detergent drug solubilizer used in the marketed product Taxotere®. Furthermore, when administered at either their respective maximum tolerated doses or at equimolar doses to free docetaxel, the two HDPN preparations produced greater antitumor activity, as measured by tumor growth delay, than the free docetaxel.  These results confirm
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
2. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
3. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
4. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
5. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
6. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
7. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
8. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
10. Poniard Pharmaceuticals Announces $6.3 Million Financing
11. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014  Amerigen ... Ltd, ("Menovo") today announced they had entered into a ... targeting the United States market. ... will jointly develop products for Amerigen to commercialize in ... be responsible for manufacturing API and finished product whereas ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
(Date:8/27/2014)... -- After the February 2014 launch of their new ... medical practices and management companies, Prime Clinical is reporting ... "The feedback has been great," says Director of ... of demos and new sign-ups is a reflection of ... of software features." Prime Clinical developed ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... 18 Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( ... announced today that its abstract, entitled "Open,Label ... and,Pharmacodynamics (PD) of Five Oral Insulin Formulations ... at the upcoming 44th Annual,Meeting of the ...
... Research Relationships and Proven, Track Record ... SANTA CLARA, Calif., Aug. 18 NewCardio, Inc.,(OTC ... company, today,announced that Vincent W. Renz has joined ... Company,s commercialization effort, to include,business development, client services, ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4
(Date:8/27/2014)... last time you experienced worrisome medical symptoms, did ... health-care professional? If so, you,re not alone. Consumers ... peer support groups to gather anecdotal information and ... and trustworthy sources. New research to be presented ... studies the characteristics of consumers who use the ...
(Date:8/27/2014)... August 27, 2014 Will Holbrook, CP ... Will has over 15 years of experience in ... in Rome, Georgia with a Bachelor of Science degree ... chemistry. He received his graduate degree in prosthetics ... excited to have Will join us at Fourroux,” says ...
(Date:8/27/2014)... -- In a new study done from the heights ... pressure steadily increases if you ascend to great heights. ... to treat high blood pressure was ineffective once climbers ... online Aug. 27 in the European Heart Journal ... at sea level who have sleep apnea, in which ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... enhancement and protection services for hospitals, is pleased to ... Inc. 5000 List of America’s Fastest-Growing Companies. The list ... of the economy—America’s independent entrepreneurs. , "It's been ... honored to be included in this year's Inc. 5000 ...
(Date:8/27/2014)... 2014 The American Brain Tumor ... the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant ... ABTA is seeding the field with talented, bright young ... of the causes, effects, diagnosis and treatment of brain ... committee based on the potential to advance the understanding ...
Breaking Medicine News(10 mins):Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3
... the tourist resort city of Livingstone were tested for bird ... backyards'. // ,Simon Miti, the permanent secretary at ... thorough investigation of the outbreak'. ,The number of ... residents who cooked and ate the dead chickens have been ...
... is found to enhance educational achievements and combat other behavioral ... that it has a positive effect on the kids suffering ... responded better to Omega 3 fish oils than to the ... found that fish oil is very essential for the kids. ...
... the killer of Lin and Megan Russell has petitioned the High ... public since it would be misused by the press. ... committed a decade ago. Stone's lawyer, Richard Clayton QC said that ... be seriously misused by the tabloid press. ,Mr Clayton ...
... Delhi Police summoned three doctors of the Indraprastha Apollo ... //on the condition of Rahul Mahajan, who was admitted ... overdose. ,"We have summoned the doctors and ... of police, heading the probe against the hospital. ...
... introduce a common school system in the country, educationists ... the primary education //system and remove disparities among students. ... school system in the country so that all students ... students," said Madhu Prasad, educationist and a professor in ...
... According to a new study published in the Journal ... epileptic seizures by inducing rhythmical //electrical activity in the ... the hippocampus. The researchers found that, by imposing a ... reduce epileptic seizures by 86-97%. ,The study ...
Cached Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: